Nasdaq · CIK 0001835579
IMA ImageneBio, Inc.
Insider trading from SEC Form 4. Last filing Jan 2, 2026. Close $4.24 on Oct 9, 2026, 0% from the 52-week low and -52% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
10
with a Form 4 at this company
Price and insider trades, last year
IMAOct 9, 2026 · close 4.24
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at ImageneBio, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 33Weak | Joseph P Slattery director buy | $96k 16,000 shares | - | - | |
| 54Moderate | David P Bonita director buy | $2.5M 83,611 shares | +41% | - | |
| 58Moderate | Otello Stampacchia director buy | $8.0M 267,556 shares | +143% | - |
Transactions
The last 31 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Dec 30, 2025 | Erin Butler Principal Accounting Officer | AGrant or award Common Stock | +22,500 | $0.00 | $0 | 25,551 | Jan 2, 2026 |
| Dec 30, 2025 | Erin Butler Principal Accounting Officer | AGrant or award Employee Stock Option (right to buy)derivative | +22,500 | $0.00 | $0 | 22,500 | Jan 2, 2026 |
| Dec 24, 2025 | Joseph P Slattery director | POpen-market purchase Common Stock | +16,000 | $5.99 | $96k | 16,000 | Dec 29, 2025 |
| Dec 18, 2025 | Joseph P Slattery director | AGrant or award Employee Stock Option (Right to Buy)derivative | +31,200 | $0.00 | $0 | 31,200 | Dec 22, 2025 |
| Dec 18, 2025 | Jonathan Jian Wang director | AGrant or award Employee Stock Option (Right to Buy)derivative | +31,200 | $0.00 | $0 | 31,200 | Dec 22, 2025 |
| Dec 18, 2025 | Stephen Hui Wang director | AGrant or award Employee Stock Option (Right to Buy)derivative | +31,200 | $0.00 | $0 | 31,200 | Dec 22, 2025 |
| Jul 25, 2025 | Stephen Hui Wang director | AGrant or award Common Stockindirect: HLC Healthcare HK Limited | +188,042 | - | - | 188,042 | Oct 10, 2025 |
| Jul 25, 2025 | Stephen Hui Wang director | AGrant or award Common Stockindirect: By Galaxy Alpha L.P. | +50,144 | - | - | 50,144 | Oct 10, 2025 |
| Jul 25, 2025 | Stephen Hui Wang director | AGrant or award Common Stockindirect: By Magic Hat L.P. | +12,535 | - | - | 12,535 | Oct 10, 2025 |
| Jul 25, 2025 | Jonathan Jian Wang director | AGrant or award Common Stock | +143,832 | - | - | 143,832 | Aug 15, 2025 |
| Jul 25, 2025 | Jonathan Jian Wang director | AGrant or award Common Stockindirect: By Engene Inc. | +971,173 | - | - | 971,173 | Aug 15, 2025 |
| Jul 25, 2025 | Yufang Lu Chief Medical Officer | AGrant or award Employee Stock Option (right to buy)derivative | +38,137 | - | - | 38,137 | Aug 7, 2025 |
| Jul 25, 2025 | Yufang Lu Chief Medical Officer | AGrant or award Employee Stock Option (right to buy)derivative | +27,459 | - | - | 27,459 | Aug 7, 2025 |
| Jul 25, 2025 | Yufang Lu Chief Medical Officer | AGrant or award Employee Stock Option (right to buy)derivative | +4,591 | - | - | 4,591 | Aug 7, 2025 |
| Jul 25, 2025 | Yufang Lu Chief Medical Officer | AGrant or award Employee Stock Option (right to buy)derivative | +6,102 | - | - | 6,102 | Aug 7, 2025 |
| Jul 25, 2025 | David P Bonita director | MOption exercise Common Stock | +379 | - | - | 379 | Jul 30, 2025 |
| Jul 28, 2025 | Kristin Yarema Chief Executive Officer | AGrant or award Employee Stock Option (Right to Buy)derivative | +460,515 | $0.00 | $0 | 460,515 | Jul 30, 2025 |
| Jul 25, 2025 | Orbimed Advisors LLC director | AGrant or award Common Stockindirect: See Footnote | +83,611 | $2.49 | $208k | 287,885 | Jul 30, 2025 |
| Jul 25, 2025 | Otello Stampacchia director | MOption exercise Common Stock | +379 | - | - | 379 | Jul 30, 2025 |
| Jul 25, 2025 | Otello Stampacchia director | POpen-market purchase Common Stockindirect: Omega Fund VI, L.P. | +267,556 | $29.90 | $8.0M | 454,982 | Jul 30, 2025 |
| Jul 28, 2025 | Kristin Yarema Chief Executive Officer | AGrant or award Restricted Stock Unitsderivative | +153,505 | $0.00 | $0 | 153,505 | Jul 30, 2025 |
| Jul 25, 2025 | David P Bonita director | POpen-market purchase Common Stockindirect: See Footnote | +83,611 | $29.90 | $2.5M | 287,885 | Jul 30, 2025 |
| Jul 25, 2025 | Otello Stampacchia director | MOption exercise Stock Option (right to buy)derivative | -17,520 | $0.00 | $0 | 0 | Jul 30, 2025 |
| Jul 25, 2025 | David P Bonita director | MOption exercise Stock Option (right to buy)derivative | -17,520 | $0.00 | $0 | 0 | Jul 30, 2025 |
| Jul 25, 2025 | Erin Butler Principal Accounting Officer | AGrant or award Common Stock | +3,051 | - | - | 3,051 | Jul 29, 2025 |
| Jul 28, 2025 | Jotin Marango Chief Financial Officer | AGrant or award Common Stock | +15,776 | - | - | 15,776 | Jul 29, 2025 |
| Jul 25, 2025 | Erin Butler Principal Accounting Officer | AGrant or award Employee Stock Option (right to buy)derivative | +3,813 | - | - | 3,813 | Jul 29, 2025 |
| Jul 28, 2025 | Jotin Marango Chief Financial Officer | FTax withholding Common Stock | -4,630 | $17.16 | $79k | 11,146 | Jul 29, 2025 |
| Jul 25, 2025 | Jotin Marango Chief Financial Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -181,000 | $0.00 | $0 | 0 | Jul 29, 2025 |
| Jul 25, 2025 | Jotin Marango Chief Financial Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -105,000 | $0.00 | $0 | 0 | Jul 29, 2025 |
| Jul 25, 2025 | Jotin Marango Chief Financial Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -397,199 | $0.00 | $0 | 0 | Jul 29, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- David P Bonitadirector, owner
- Erin ButlerPrincipal Accounting Officer
- Yufang LuChief Medical Officer
- Jotin MarangoChief Financial Officer
- Orbimed Advisors LLCdirector, owner
- Joseph P Slatterydirector
- Otello Stampacchiadirector
- Jonathan Jian Wangdirector
- Stephen Hui Wangdirector
- Kristin YaremaChief Executive Officer
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.